Delivery of siRNAs to dendritic cells using DEC205-targeted lipid nanoparticles to inhibit immune responses

Joseph A. Katakowski, Gayatri Mukherjee, Samantha E. Wilner, Keith E. Maier, Michael Travis Harrison, Teresa P. DiLorenzo, Matthew Levy, Deborah Palliser

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Due to their ability to knock down the expression of any gene, siRNAs have been heralded as ideal candidates for treating a wide variety of diseases, including those involving "undruggable" targets. However, the therapeutic potential of siRNAs remains severely limited by a lack of effective delivery vehicles. Recently, lipid nanoparticles (LNPs) containing ionizable cationic lipids have been developed for hepatic siRNA delivery. However, their suitability for delivery to other cell types has not been determined. We have modified LNPs for preferential targeting to dendritic cells (DCs), central regulators of immune responses. To achieve directed delivery, we coated LNPs with a single-chain antibody (scFv; DEC-LNPs), specific to murine DEC205, which is highly expressed on distinct DC subsets. Here we show that injection of siRNAs encapsulated in DEC-LNPs are preferentially delivered to DEC205 + DCs. Gene knockdown following uptake of DEC-LNPs containing siRNAs specific for the costimulatory molecules CD40, CD80, and CD86 dramatically decreases gene expression levels. We demonstrate the functionality of this knockdown with a mixed lymphocyte response (MLR). Overall, we report that injection of LNPs modified to restrict their uptake to a distinct cell population can confer profound gene knockdown, sufficient to inhibit powerful immune responses like the MLR.

Original languageEnglish (US)
Pages (from-to)146-155
Number of pages10
JournalMolecular Therapy
Volume24
Issue number1
DOIs
StatePublished - Feb 1 2016

Fingerprint

Nanoparticles
Dendritic Cells
Lipids
Gene Knockdown Techniques
Lymphocytes
Gene Expression
Single-Chain Antibodies
Injections
Small Interfering RNA
Liver
Population

ASJC Scopus subject areas

  • Molecular Biology
  • Molecular Medicine
  • Genetics
  • Drug Discovery
  • Pharmacology

Cite this

Katakowski, J. A., Mukherjee, G., Wilner, S. E., Maier, K. E., Harrison, M. T., DiLorenzo, T. P., ... Palliser, D. (2016). Delivery of siRNAs to dendritic cells using DEC205-targeted lipid nanoparticles to inhibit immune responses. Molecular Therapy, 24(1), 146-155. https://doi.org/10.1038/mt.2015.175

Delivery of siRNAs to dendritic cells using DEC205-targeted lipid nanoparticles to inhibit immune responses. / Katakowski, Joseph A.; Mukherjee, Gayatri; Wilner, Samantha E.; Maier, Keith E.; Harrison, Michael Travis; DiLorenzo, Teresa P.; Levy, Matthew; Palliser, Deborah.

In: Molecular Therapy, Vol. 24, No. 1, 01.02.2016, p. 146-155.

Research output: Contribution to journalArticle

Katakowski, JA, Mukherjee, G, Wilner, SE, Maier, KE, Harrison, MT, DiLorenzo, TP, Levy, M & Palliser, D 2016, 'Delivery of siRNAs to dendritic cells using DEC205-targeted lipid nanoparticles to inhibit immune responses', Molecular Therapy, vol. 24, no. 1, pp. 146-155. https://doi.org/10.1038/mt.2015.175
Katakowski, Joseph A. ; Mukherjee, Gayatri ; Wilner, Samantha E. ; Maier, Keith E. ; Harrison, Michael Travis ; DiLorenzo, Teresa P. ; Levy, Matthew ; Palliser, Deborah. / Delivery of siRNAs to dendritic cells using DEC205-targeted lipid nanoparticles to inhibit immune responses. In: Molecular Therapy. 2016 ; Vol. 24, No. 1. pp. 146-155.
@article{fa44f86932644f90bfd8a2aaf16b27cd,
title = "Delivery of siRNAs to dendritic cells using DEC205-targeted lipid nanoparticles to inhibit immune responses",
abstract = "Due to their ability to knock down the expression of any gene, siRNAs have been heralded as ideal candidates for treating a wide variety of diseases, including those involving {"}undruggable{"} targets. However, the therapeutic potential of siRNAs remains severely limited by a lack of effective delivery vehicles. Recently, lipid nanoparticles (LNPs) containing ionizable cationic lipids have been developed for hepatic siRNA delivery. However, their suitability for delivery to other cell types has not been determined. We have modified LNPs for preferential targeting to dendritic cells (DCs), central regulators of immune responses. To achieve directed delivery, we coated LNPs with a single-chain antibody (scFv; DEC-LNPs), specific to murine DEC205, which is highly expressed on distinct DC subsets. Here we show that injection of siRNAs encapsulated in DEC-LNPs are preferentially delivered to DEC205 + DCs. Gene knockdown following uptake of DEC-LNPs containing siRNAs specific for the costimulatory molecules CD40, CD80, and CD86 dramatically decreases gene expression levels. We demonstrate the functionality of this knockdown with a mixed lymphocyte response (MLR). Overall, we report that injection of LNPs modified to restrict their uptake to a distinct cell population can confer profound gene knockdown, sufficient to inhibit powerful immune responses like the MLR.",
author = "Katakowski, {Joseph A.} and Gayatri Mukherjee and Wilner, {Samantha E.} and Maier, {Keith E.} and Harrison, {Michael Travis} and DiLorenzo, {Teresa P.} and Matthew Levy and Deborah Palliser",
year = "2016",
month = "2",
day = "1",
doi = "10.1038/mt.2015.175",
language = "English (US)",
volume = "24",
pages = "146--155",
journal = "Molecular Therapy",
issn = "1525-0016",
publisher = "Nature Publishing Group",
number = "1",

}

TY - JOUR

T1 - Delivery of siRNAs to dendritic cells using DEC205-targeted lipid nanoparticles to inhibit immune responses

AU - Katakowski, Joseph A.

AU - Mukherjee, Gayatri

AU - Wilner, Samantha E.

AU - Maier, Keith E.

AU - Harrison, Michael Travis

AU - DiLorenzo, Teresa P.

AU - Levy, Matthew

AU - Palliser, Deborah

PY - 2016/2/1

Y1 - 2016/2/1

N2 - Due to their ability to knock down the expression of any gene, siRNAs have been heralded as ideal candidates for treating a wide variety of diseases, including those involving "undruggable" targets. However, the therapeutic potential of siRNAs remains severely limited by a lack of effective delivery vehicles. Recently, lipid nanoparticles (LNPs) containing ionizable cationic lipids have been developed for hepatic siRNA delivery. However, their suitability for delivery to other cell types has not been determined. We have modified LNPs for preferential targeting to dendritic cells (DCs), central regulators of immune responses. To achieve directed delivery, we coated LNPs with a single-chain antibody (scFv; DEC-LNPs), specific to murine DEC205, which is highly expressed on distinct DC subsets. Here we show that injection of siRNAs encapsulated in DEC-LNPs are preferentially delivered to DEC205 + DCs. Gene knockdown following uptake of DEC-LNPs containing siRNAs specific for the costimulatory molecules CD40, CD80, and CD86 dramatically decreases gene expression levels. We demonstrate the functionality of this knockdown with a mixed lymphocyte response (MLR). Overall, we report that injection of LNPs modified to restrict their uptake to a distinct cell population can confer profound gene knockdown, sufficient to inhibit powerful immune responses like the MLR.

AB - Due to their ability to knock down the expression of any gene, siRNAs have been heralded as ideal candidates for treating a wide variety of diseases, including those involving "undruggable" targets. However, the therapeutic potential of siRNAs remains severely limited by a lack of effective delivery vehicles. Recently, lipid nanoparticles (LNPs) containing ionizable cationic lipids have been developed for hepatic siRNA delivery. However, their suitability for delivery to other cell types has not been determined. We have modified LNPs for preferential targeting to dendritic cells (DCs), central regulators of immune responses. To achieve directed delivery, we coated LNPs with a single-chain antibody (scFv; DEC-LNPs), specific to murine DEC205, which is highly expressed on distinct DC subsets. Here we show that injection of siRNAs encapsulated in DEC-LNPs are preferentially delivered to DEC205 + DCs. Gene knockdown following uptake of DEC-LNPs containing siRNAs specific for the costimulatory molecules CD40, CD80, and CD86 dramatically decreases gene expression levels. We demonstrate the functionality of this knockdown with a mixed lymphocyte response (MLR). Overall, we report that injection of LNPs modified to restrict their uptake to a distinct cell population can confer profound gene knockdown, sufficient to inhibit powerful immune responses like the MLR.

UR - http://www.scopus.com/inward/record.url?scp=84957844235&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84957844235&partnerID=8YFLogxK

U2 - 10.1038/mt.2015.175

DO - 10.1038/mt.2015.175

M3 - Article

C2 - 26412590

AN - SCOPUS:84957844235

VL - 24

SP - 146

EP - 155

JO - Molecular Therapy

JF - Molecular Therapy

SN - 1525-0016

IS - 1

ER -